Drugs / Naltrexone/bupropion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03374956 | Dec 2017 → May 2022 | obesity disorder | Mayo Clinic | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Naltrexone/bupropion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03374956 ↗ |
| Route | Oral | “32/360 mg oral daily” NCT03374956 ↗ |